Table 1 Patient characteristics and clinicopathological variables of the study cohort based on national cancer quality registry data.
All samples | ER+/HER2−/LN+ | ER+/HER2−/LN− | HER2+/ER+ | HER2+/ER− | TNBC | |
|---|---|---|---|---|---|---|
Number of samples | 3520 | 943 | 1527 | 321 | 140 | 340 |
ER status (%) | ||||||
Negative (ER IHC ≤ 10%)* | 14.5 | 0 | 0 | 0 | 100 | 100 |
Positive (ER IHC > 10%)* | 84.2 | 100 | 100 | 100 | 0 | 0 |
NA | 1.3 | 0 | 0 | 0 | 0 | 0 |
PR status (%) | ||||||
Negative (PR IHC ≤ 10%)* | 26.5 | 13 | 12 | 32 | 96 | 100 |
Positive (PR IHC > 10%)* | 72.1 | 87 | 88 | 68 | 4 | 0 |
NA | 1.4 | 0 | 0 | 0 | 0 | 0 |
HER2 status (%) | ||||||
Negative | 82.4 | 100 | 100 | 0 | 0 | 100 |
Positive | 13.2 | 0 | 0 | 100 | 100 | 0 |
NA | 4.4 | 0 | 0 | 0 | 0 | 0 |
Age (median and range) | 65 (25–100) | 65 (25–95) | 65 (30–100) | 63 (30–95) | 70 (35–95) | 65 (30–95) |
Tumor size (median mm and range) | 17 (0–126) | 20 (0–126) | 15 (1–110) | 18 (1–120) | 20.5 (0–70) | 20 (0–100) |
NHG (%) | ||||||
1 | 15 | 13 | 24 | 2 | 0 | 1 |
2 | 47 | 56 | 55 | 30 | 11 | 11 |
3 | 36 | 30 | 20 | 66 | 84 | 84 |
NA | 2 | 2 | 1 | 3 | 4 | 3 |
Lymph node status (%) | ||||||
0 positive nodes | 59 | 0 | 100 | 54 | 43 | 64 |
1–3 positive nodes | 27 | 71 | 0 | 27 | 31 | 24 |
≥4 positive nodes | 9 | 23 | 0 | 12 | 19 | 8 |
Sub micro metastasis | 2 | 6 | 0 | 3 | 2 | 2 |
NA | 3 | 0 | 0 | 4 | 6 | 2 |
Treatment (%) | All samples | ER+/HER2−/LN+ | ER+/HER2−/LN− | HER2+/ER+ | HER2+/ER− | TNBC |
Endocrine only | 49 | 48 | 71 | 17 | 1 | 1 |
ACT only | 8 | 1 | 0 | 0 | 1 | 70 |
Endocrine & ACT | 22 | 49 | 15 | 2.5 | 0 | 1 |
Anti-HER2 & ACT | 3 | 0 | 0 | 2 | 79 | 1 |
Anti-HER2 & ACT & endocrine | 8 | 0.7 | 0 | 74 | 6 | 0 |
Untreated | 10 | 1.6 | 13 | 3 | 8 | 24 |
NA or other combination | 0 | 0 | 1 | 1.5 | 5 | 3 |
